LAG3 and melanoma: Ngiow et al. also showed that CD94/NKG2 expression on exhausted CD8+ T cells can be recalibrated by injection of anti-LAG-3 and anti-PD-1 antibodies (called relatlimab and nivolumab, respectively) in mice and humans in the context of melanoma, proofing a therapeutic potential.